title: The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
authors.forename: Meletios Athanasios
authors.initials: MA
authors.lastname: Dimopoulos
authors.forename: Efstathios
authors.initials: E
authors.lastname: Kastritis
authors.forename: Sossana
authors.initials: S
authors.lastname: Delimpassi
authors.forename: Athanasios
authors.initials: A
authors.lastname: Zomas
authors.forename: Marie Christine
authors.initials: MC
authors.lastname: Kyrtsonis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Zervas
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011379:Prognosis; D000069283:Rituximab; D012955:Societies, Medical; D015996:Survival Rate; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab